BSEM
BioStem Technologies, Inc.
Set alert
- YTD
- -70.60%
- 1 year
- -75.86%
- Open
- 1.28
- Prev close
- 1.29
- Mkt cap
- 20.91M
- Vol
- 145.59K
- Avg vol
- 151.55K
- EPS
- 0.88
- P/E
- 1.27
- Div yield
- 0.00%
More statistics
- Low
- 1.11
- High
- 1.29
- Earnings
- Aug 12, 2024
News
1 day ago globenewswire.com
BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026
POMPANO BEACH, Fla., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
3 weeks ago prismmediawire.com
BioStem Technologies' CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options
Leadership investment supports expanded hospital commercial push PR Audio: POMPANO BEACH, Fla., October 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem…
3 weeks ago globenewswire.com
BioStem Technologies' CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options
POMPANO BEACH, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
3 weeks ago defenseworld.net
Century Therapeutics (NASDAQ:IPSC) and BioStem Technologies (OTCMKTS:BSEM) Financial Analysis
Century Therapeutics (NASDAQ: IPSC - Get Free Report) and BioStem Technologies (OTCMKTS:BSEM - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will…
-
4 weeks ago benzinga.com
BioStem Secures US Patent, Additional US And Mexico Allowances For Tissue Technologies
BioStem Technologies, Inc. (NASDAQ:BSEM) ("BioStem" or the "Company"), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue
4 weeks ago prismmediawire.com
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
Newly issued U.S. Patent and pending allowances in the U.S. and Mexico extend protection for the company's sterile placental allograft, micronized wound care, and umbilical cord extract technologies…
4 weeks ago globenewswire.com
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
POMPANO BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
1 month ago prismmediawire.com
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
POMPANO BEACH, Fla., September 30, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies Inc.
1 month ago globenewswire.com
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
1 month ago globenewswire.com
Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform
West Palm Beach, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1…
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers IM Cannabis (NASDAQ:IMCC) stock increased by 246.0% to $6.02 during Friday's regular session. The market value of their outstanding shares is at $1.0 million. SkyAI (NASDAQ:SKYA) stock rose…
1 month ago prismmediawire.com
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
PR Audio: PR Video Overview: POMPANO BEACH, Fla., September 18, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
1 month ago globenewswire.com
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
POMPANO BEACH, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
1 month ago prismmediawire.com
BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
Additions extend BioStem's hospital channel to its BioRetain® wound care line PR Audio: POMPANO BEACH, Fla., September 4, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) –…
1 month ago globenewswire.com
BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
POMPANO BEACH, Fla., Sept. 04, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
1 month ago globenewswire.com
BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
POMPANO BEACH, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
2 months ago marketbeat.com
BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal
BioStem Technologies OTCMKTS: BSEM outlined its strategy to expand in surgical applications, shift its revenue mix away from physician-office wound care and bring manufacturing of acquired products…
2 months ago defenseworld.net
Comparing BioStem Technologies (OTCMKTS:BSEM) and Enlivex Therapeutics (NASDAQ:ENLV)
BioStem Technologies (OTCMKTS:BSEM - Get Free Report) and Enlivex Therapeutics (NASDAQ: ENLV - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will…
2 months ago globenewswire.com
BioStem Technologies to Present at the Sidoti MicroCap Conference
POMPANO BEACH, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regular session. The market value of their outstanding shares is at $7.2 million. BeyondSpring (NASDAQ:BYSI)…
2 months ago marketbeat.com
BioStem Technologies Q2 Earnings Call Highlights
BioStem Technologies OTCMKTS: BSEM reported second-quarter revenue of $7.9 million as the company continued its transition to a predominantly hospital-focused commercial model. Revenue increased from…
2 months ago seekingalpha.com
BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates
BioStem Technologies, Inc. (BSEM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to earnings of $0.11 per share a year ago.
-
2 months ago benzinga.com
BioStem Technologies Q2 EPS $(0.52), Sales $7.899M Down From $10.963M YoY
BioStem Technologies (NASDAQ:BSEM) reported quarterly losses of $(0.52) per share. The company reported $7.899 million in sales this quarter. This is a 27.95 percent decrease over sales of $10.963…
-
2 months ago benzinga.com
BioStem Technologies Announces It Received Nasdaq Approval For The Company’s Common Stock For Listing On The Nasdaq Capital Market; Co. To Begin Trading On Nasdaq On August 7, 2026 Under The Ticker Symbol "BSEM"
BioStem Technologies Inc. (OTC:BSEM) ("BioStem" or the "Company"), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue…
-
3 months ago benzinga.com
Biostem Technologies Files Form 10 Share Registration Statement With The SEC; Reaffirms Planned Nasdaq Listing
"The filing of our Registration Statement is an important milestone that advances our path toward a Nasdaq uplisting and reflects our significant commitment to operating as an SEC reporting company,"…
-
3 years ago benzinga.com
NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova Allograft
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) and BioStem Technologies, Inc. (OTC:BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies' Amniotic…
-
4 years ago benzinga.com
EXCLUSIVE: BioStem Technologies Reports Q1 Net Revenue Up 211% YoY
BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics today, reported financial results…